Literature DB >> 21333935

A review of pain experienced during topical photodynamic therapy--our experience in Dundee.

Sasi Kiran Attili1, Robert Dawe, Sally Ibbotson.   

Abstract

BACKGROUND: Topical photodynamic therapy (PDT) using 5-aminolaevulinic acid (ALA) and its methylated ester, methyl aminolevulinate (MAL) is widely used to treat superficial non-melanoma skin cancer (NMSC). It has been proposed that ALA PDT is more painful than MAL PDT. The aim of this paper was to compare pain scores of MAL PDT with ALA PDT in our patients and to analyse the relationship between various parameters and pain during PDT.
METHODS: We retrospectively reviewed case notes and electronic records for all patients with superficial NMSC treated with PDT from June 2007 to March 2009.
RESULTS: On univariate analysis of patients with single lesions only, we observed no association between pain and lesion diameter or pro-drug or dose or diagnosis. Pre-treatment PpIX fluorescence was significantly associated with pain. However on univariate analysis of all patients (whether single or multiple lesions) treated with PDT, MAL was associated with significantly less pain than ALA. When all the recorded variables were taken into account (multivariate analysis), diagnosis, pre-treatment PpIX fluorescence and lesion diameter were associated with pain.
CONCLUSIONS: Our data lends some support to previous published reports suggesting that the MAL PDT regime is less painful than that for ALA PDT. However, PDT pain is multifactorial and choice of photosensitiser is probably not a major pain determining factor. A prospective randomised study, with the same incubation periods for each pro-drug, is needed to definitively answer the question as to whether or not MAL PDT causes less pain than ALA PDT.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21333935     DOI: 10.1016/j.pdpdt.2010.12.008

Source DB:  PubMed          Journal:  Photodiagnosis Photodyn Ther        ISSN: 1572-1000            Impact factor:   3.631


  10 in total

1.  A prospective study of pain control by a 2-step irradiance schedule during topical photodynamic therapy of nonmelanoma skin cancer.

Authors:  Nathalie C Zeitouni; Ulas Sunar; Daniel J Rohrbach; Anne D Paquette; David A Bellnier; Yi Shi; Gregory Wilding; Thomas H Foster; Barbara W Henderson
Journal:  Dermatol Surg       Date:  2014-12       Impact factor: 3.398

2.  Assessing daylight & low-dose rate photodynamic therapy efficacy, using biomarkers of photophysical, biochemical and biological damage metrics in situ.

Authors:  Ana Luiza Ribeiro de Souza; Ethan LaRochelle; Kayla Marra; Jason Gunn; Scott C Davis; Kimberley S Samkoe; M Shane Chapman; Edward V Maytin; Tayyaba Hasan; Brian W Pogue
Journal:  Photodiagnosis Photodyn Ther       Date:  2017-10-14       Impact factor: 3.631

3.  Novel Water-Soluble Chlorin-Based Photosensitizer for Low-Fluence Photodynamic Therapy.

Authors:  Liu Wang; Guangzhe Li; Lei Cao; Kun Shao; Yueqing Li; Xi Zhang; Jianzhang Zhao; Weijie Zhao
Journal:  ACS Pharmacol Transl Sci       Date:  2022-01-21

4.  Dual-channel red/blue fluorescence dosimetry with broadband reflectance spectroscopic correction measures protoporphyrin IX production during photodynamic therapy of actinic keratosis.

Authors:  Stephen Chad Kanick; Scott C Davis; Yan Zhao; Tayyaba Hasan; Edward V Maytin; Brian W Pogue; M Shane Chapman
Journal:  J Biomed Opt       Date:  2014       Impact factor: 3.170

5.  A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer.

Authors:  Nathalie C Zeitouni; Anne D Paquette; Joseph P Housel; Yi Shi; Gregory E Wilding; Thomas H Foster; Barbara W Henderson
Journal:  Lasers Surg Med       Date:  2013-02-06       Impact factor: 4.025

6.  Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.

Authors:  S C Kanick; S C Davis; Y Zhao; K L Sheehan; T Hasan; E V Maytin; B W Pogue; M S Chapman
Journal:  Photodiagnosis Photodyn Ther       Date:  2015-10-22       Impact factor: 3.631

Review 7.  Combined Treatments with Photodynamic Therapy for Non-Melanoma Skin Cancer.

Authors:  Silvia Rocío Lucena; Nerea Salazar; Tamara Gracia-Cazaña; Alicia Zamarrón; Salvador González; Ángeles Juarranz; Yolanda Gilaberte
Journal:  Int J Mol Sci       Date:  2015-10-28       Impact factor: 5.923

Review 8.  Thionated organic compounds as emerging heavy-atom-free photodynamic therapy agents.

Authors:  Luis A Ortiz-Rodríguez; Carlos E Crespo-Hernández
Journal:  Chem Sci       Date:  2020-09-22       Impact factor: 9.825

Review 9.  Early and Late Onset Side Effects of Photodynamic Therapy.

Authors:  Francesco Borgia; Roberta Giuffrida; Emanuela Caradonna; Mario Vaccaro; Fabrizio Guarneri; Serafinella P Cannavò
Journal:  Biomedicines       Date:  2018-01-29

10.  Smartphone fluorescence imager for quantitative dosimetry of protoporphyrin-IX-based photodynamic therapy in skin.

Authors:  Alberto J Ruiz; Ethan Phillip M LaRochelle; Jason R Gunn; Sally M Hull; Tayyaba Hasan; M Shane Chapman; Brian W Pogue
Journal:  J Biomed Opt       Date:  2019-12       Impact factor: 3.170

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.